1. Home
  2. NSPR vs DBVT Comparison

NSPR vs DBVT Comparison

Compare NSPR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.79

Market Cap

81.8M

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$19.21

Market Cap

769.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
DBVT
Founded
2005
2002
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.8M
769.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NSPR
DBVT
Price
$1.79
$19.21
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$4.00
$31.75
AVG Volume (30 Days)
59.6K
709.3K
Earning Date
11-04-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,779,000.00
$5,502,000.00
Revenue This Year
$22.76
$1,768.71
Revenue Next Year
$75.45
$1,028.88
P/E Ratio
N/A
N/A
Revenue Growth
14.04
N/A
52 Week Low
$1.59
$2.99
52 Week High
$3.80
$26.19

Technical Indicators

Market Signals
Indicator
NSPR
DBVT
Relative Strength Index (RSI) 39.81 56.06
Support Level $1.89 $18.46
Resistance Level $2.15 $19.90
Average True Range (ATR) 0.15 1.51
MACD -0.01 -0.19
Stochastic Oscillator 25.49 18.36

Price Performance

Historical Comparison
NSPR
DBVT

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: